To determine whether cytomegalovirus (CMV) disease is an independent risk factor for graft loss and death after orthotopic liver transplantation, we performed a 3-year follow-up study of 143 consecutive liver transplant recipients and six patients who underwent retransplantation. Thirtyseven patients (25%) had had CMV disease and were alive after treatment. Fifty-two deaths and eight graft losses occurred. The cumulative incidence of graft failure at 1 and 3 years of follow-up were 40% and 63%, respectively, for patients with CMV disease, compared with 22% and 33%, respectively, for those without CMV disease (P õ .05, logrank test). Cumulative probabilities of survival for patients with and without CMV disease were 64% and 82%, respectively, at 1 year and 46% and 69%, respectively, after 3 years (P õ .05, logrank test). Multivariate analysis with use of a time-dependent Cox model showed that previous CMV disease was an independent risk factor for graft loss at 1 and 3 years of follow-up (P Å .04 and P Å .007) and for patient survival (P Å .04 and P Å .01). Our results indicate that CMV disease is a significant independent risk factor for graft loss and patient survival after liver transplantation.
tistical comparisons were carried out by using the method of Mantel-Cox (logrank test). Only variables that showed a statistical association with the 1-year or 3-year mortality or graft loss rates on univariate analysis were included as candidate 16 -66 years). The most common indication for transplantation was cirrhosis due to hepatitis C virus (48.2% of patients), variables for forward stepwise selection in the multivariate time-dependent Cox model analysis. Univariate and multivarifollowed by alcoholic cirrhosis (43.3%). Thirty transplant recipients were CMV seropositive but received CMV-negative ate analyses were performed with SPSS (SPSS, Inc., Chicago) version 6.0 for Windows. Differences were considered to be donor organs (D0/R/), nine were D//R0, five were D0/R0, and 99 were D///. Baseline characteristics of the patients are significant at P values of õ.05.
shown in table 1. CMV disease occurred in 46 (32.2%) of the 143 patients.
Results
Twenty-six patients had CMV hepatitis, six had CMV syndrome, seven had pneumonia, one had gastrointestinal CMV We studied 143 patients who underwent OLT and six patients who underwent retransplantation. The mean duration of disease, and six had disseminated CMV disease. Eleven cases (23.9%) were diagnosed during the first month after OLT, and follow-up was 774 days (range, 31 -1,095 days). The median age of the 95 men and 48 women studied was 54 years (range, 38 (82.6%) occurred during the first 6 months after OLT. In / 9c4a$$ap59 03-07-98 00:53:08 cida UC: CID The cumulative probabilities of survival for patients with and days before death. Only one of these nine patients (a patient without CMV disease were 63.8% and 82.2%, respectively, at with disseminated CMV disease) died of CMV disease. These 1 year of follow-up and 45.9% and 68.9%, respectively, after nine CMV disease episodes were not included in the analysis 3 years of follow-up (P õ .05, logrank test). of risk factors for death.
Results of multivariate time-dependent Cox model analysis Ninety-one of the 143 patients studied were alive at the end with use of the variables that were significantly associated on of follow-up. Sixty of 149 grafts included in the graft survival univariate analysis confirmed the importance of previous CMV analysis had been lost at the end of follow-up. Two cases of disease as an independent risk factor for graft loss at 1 and 3 graft loss occurred after the recruitment period, and the patients, years of follow-up (P Å .04 and P Å .007, respectively) and who underwent retransplantation, were not included in the analfor death (P Å .04 and P Å .01, respectively). The analysis ysis. The causes of the 52 deaths and the eight graft losses are disclosed that acute rejection (for graft loss and death at 1 and shown in table 2. The most common cause of death after 3 3 years of follow-up), positive crossmatch (for survival after years of follow-up was an infectious disease (70% of cases). Bacterial infection (either sepsis or pneumonia) was the leading 3 years of follow-up), and chronic rejection (for graft loss after 3 years of follow-up) were also independent risk factors (ta-CMV is the single most important infectious agent affecting liver transplant recipients, and there is evidence of CMV infecble 5).
tion in at least two-thirds of these individuals [2] . During the last few years, substantial progress has been made in the manDiscussion agement of CMV infection, but CMV infection remains a major source of morbidity after OLT despite the many advances in OLT has undergone tremendous development over the past 10 years and is now considered to be routine treatment for early diagnosis and treatment. It has been reported that CMV infection may predispose to other opportunistic infections, esend-stage liver disease. It is therefore relevant to determine the prognosis for patients who have undergone OLT and to pecially those due to P. carinii, Aspergillus fumigatus, Candida albicans, and gram-negative bacilli, in patients undergoing understand the factors that are related to mortality, and it is particularly important to identify risk factors for graft loss or solid organ transplantation [2 -8] . Other indirect effects of CMV infection are related to immunomodulation, i.e., inducdeath that may be modified to improve outcome.
Technical problems and acute rejection have become less imtion of the vanishing bile duct syndrome in liver transplant recipients [9 -13] and a more severe histological progression portant as risk factors for death among orthotopic liver transplant recipients, and infection and chronic rejection have become inof chronic hepatitis in liver recipients with posttransplantation hepatitis C virus infection [14, 15] . Despite these documented creasing problems for these patients [18, 19] . The risk factors for graft loss or death that have been reported to date include effects, the indirect impact of CMV infection on graft and patient survival has not been extensively studied. Preliminary pretransplantation encephalopathy and prolonged partial thromboplastin time [20] , urgency of liver transplantation [21] , HLA comreports have indicated that CMV infection has no effect on survival [29] , but recent data suggest that CMV infection or patibility [22, 23] , use of FK506 in patients with chronic hepatitis C infection who undergo OLT [24] , liver diseases of the recipients disease could have an influence on patient and graft survival among liver transplant recipients [30, 31] . (e.g., chronic hepatitis B and primary hepatic malignancy) [25, 26] , the pretransplantation serum creatinine level [27] , and ABO Donaldson et al. [30] found that primary and secondary CMV infections were associated with reduced rates of graft blood group compatibility [28] . The impact of CMV infection on survival was not evaluated in these studies.
survival following liver transplantation only for patients receiv- / 9c4a$$ap59 03-07-98 00:53:08 cida UC: CID ing triple immunosuppressive therapy (cyclosporine, prednisodeaths directly attributable to CMV. Consequently, we demonstrated that the outcome for patients with a cured episode of lone, and azathioprine). CMV infection was present in 62 (64.6%) of 96 patients with graft loss in the first year after CMV disease was poorer, with decreased rates of graft and patient survival at 1 year of follow-up. Furthermore, we found OLT and in 47 (21.3%) of 221 without graft loss (P õ .05). Van den Berg et al. [31] reviewed the records of 111 adult that there were differences in survival after a long period of follow-up (3 years). orthotopic liver transplant recipients. None of the 29 patients without CMV infection died during the first 180 days after It has been reported that CMV disease has different indirect OLT, whereas 10 (15%) of 66 patients with CMV infection effects in solid organ transplant recipients; these effects are died during that period (P õ .01, logrank test). These two related to CMV-mediated immunosuppression (superinfections studies identified the role of CMV infection as a risk factor by other opportunistic microorganisms) [2 -8] and to CMVassociated with death; however, data were obtained only with mediated activation of the immune system that may end in use of univariate analysis, and the possible effect of CMV chronic rejection of grafts [9 -13] . As is shown in our study, infection or other variables should be explored by using multimajor bacterial and fungal diseases were the most important variate analysis.
cause of death in our population. On the other hand, half of the Recently, Falagas et al. [16] investigated the effect of CMV patients who underwent retransplantation developed chronic disease on 1-year mortality rates among orthotopic liver transrejection. Likewise, in our cohort of liver transplant recipients, plant recipients by using multivariate techniques. These investi-CMV disease was a risk factor for invasive fungal disease gators analyzed a cohort of 146 liver transplant recipients and (multivariate analysis of risk factors in 27 episodes of invasive found that the presence of CMV disease was independently fungal disease and CMV disease: RR Å 4.86; 95% CI Å 2.12 -associated with higher mortality rates (RR Å 3.9, CI Å 1.8 -11.1; P Å .0002) and chronic rejection (univariate analysis of 8.5, P Å .01). Retransplantation, the total number of bloodrisk of developing chronic rejection in relation to CMV disease product units administered during transplantation, the presence at 3 years of follow-up: number of episodes of chronic rejection of invasive fungal disease, and the presence of bacteremia were Å 18; 29.2% in patients with CMV disease vs. 8.4% in patients also identified as risk factors. Falagas et al. maintain that there with no CMV disease; P Å .02). is a strong association between CMV disease and high mortality
The relation between previous CMV disease and reduced rates among orthotopic liver transplant recipients. They recogrates of graft and patient survival is of great interest. The nized that it was difficult to determine whether deaths in their mechanism underlying the poorer outcome for CMV-infected series were directly attributable to CMV disease in patients for graft recipients is still unknown, but this outcome seems to be whom the causes of death were multifactorial and who were a consequence of the indirect effects of CMV infection. The treated before more effective means of preventing or treating increased rate of opportunistic infections and the tendency to CMV disease had been instituted. In addition, it is possible develop chronic allograft dysfunction among patients with that the CMV disease in their patients was primarily a marker CMV infection or disease may contribute to the unfavorable of immunosuppression rather than a direct or indirect cause of outcome for these patients, as compared with those without death.
CMV infection. During the last decade, progress has been made Our results are similar to those reported previously. CMV in treating CMV disease, and episodes are usually treated sucdisease was an independent risk factor for reduced rates of cessfully. Our data suggest, however, that treating CMV disgraft and patient survival. Our patients with previous CMV ease is not enough to avoid its indirect effects or to reduce disease had a twofold increased risk of death or graft loss their impact on mortality. after 3 years of follow-up. Other variables were independently
The question remains as to whether CMV-associated immusignificant in the multivariate model, including acute rejection, nomodulation and subsequent superinfection or allograft dyspositive crossmatch (for survival), and chronic rejection (for function occur following CMV replication or require the presgraft loss).
ence of CMV disease. In the first case universal prophylaxis We tried to identify risk factors with the strongest indepenwould be warranted, whereas in the second case the appropriate dent effects on graft loss or mortality. In contrast to Falagas strategy would be preemptive therapy. It remains to be estabet al. [16] , we did not include major bacterial and fungal infeclished whether the mortality or rate of graft loss associated tions in our model because they are variables directly associated with CMV disease can be reduced by any prophylactic or with death and, therefore, more often represent the primary preemptive strategies. cause of death than possible predictors of mortality. We considered that including the primary causes of death as variables in the model would give erroneous results for identifying risk factors. Moreover, to fully explore the indirect effect of CMV disease group. This was done to exclude from the analysis / 9c4a$$ap59 03-07-98 00:53:08 cida UC: CID
